Generics can’t stop heart drug cartel suit

Charles McConnell

11 April 2017

A federal judge in New York held last week that indirect and direct purchasers had sufficiently alleged that several generic drugmakers orchestrated a scheme to fix and raise the price of propranolol hydrochloride.

Subscribe to Global Competition Review

Subscribe and start reading now

Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.

Subscribe now

Already have access? Login below

Charles McConnell

View full biography

Author | Senior reporter, Global Competition Review

[email protected]

Tipline

Gym class heroes: The Tipline for 30 June 2022
The Federal Trade Commission’s Democrats aren’t fans of PE. The agency’s majority sees private equity as M&A’s version of high school gym class, but instead of challenging students with shaky pushups and sweaty pullups, it's swallowing up small businesses with stealthy rollups and leveraged buyouts. For the second time this month, the commission is trumpeting the fact that it required conditional approval for a PE firm’s proposed merger – even if those assets are …
Walmart’s consumer protection paradox: The Tipline for 29 June 2022
The fix is in, preliminarily: The Tipline for 28 June 2022